Sign up
Pharma Capital
EPIC: LXG
Market: TSX-V:LXG
OTCQB:LXXGF
52-week High/Low: C$0.93 / C$0.50
Sector: Health Care, Equipment & Services
Market Cap: C$49.38M
Website: www.lexagene.com

LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge,...

Lexagene Holdings Inc

www.lexagene.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Lexagene Holdings Inc

Lexagene Holdings Inc Snapshot

Technology |
Overview

Automated, rapid and sensitive pathogen detection

LexaGene is developing a genetic analyzer for automated pathogen detection that is designed to be placed at the site of sample collection – to quickly detect multiple pathogens at once with sensitivity and specificity – and return results in about 1 hour.

The LX2™ Genetic Analyzer is being designed for syndromic testing in veterinary diagnostics and human clinical diagnostics, as well as food safety testing, water quality monitoring, and other markets that need critical answers in less time.

The technology’s open-access feature allows researchers in biotech, pharma, and academic laboratories to customize their testing, whether it is to detect rare infectious diseases, screen for cancer, or perform mRNA expression profiling.

The open-access feature also makes the system uniquely poised to become a critical part of preventing the spread of emerging strains of new infectious diseases to help avert a pandemic.

Easy-to-use
Simply load the sample and a cartridge onto the automated genetic analyzer and press ‘Go’. No pipetting or other steps are required. No need for a skilled technician

Sensitivity and specificity
Process significant sample volume for better, more accurate detection.  The analyzer uses real-time PCR for ultra-sensitive detection, and its high level of multiplexing allows for improved specificity.

Low cost per test
The system uses microfluidics to draw reagents from bulk reservoirs, as opposed to having reagents embedded inside single-use fully integrated cartridges, which are expensive to manufacture.

Compact
The analyzer’s powerful functionality is contained in a small footprint for placement in cramped clinics, food plants, and processing facilities.

Fast results – onsite
Test onsite, process 2 samples at a time. Rapid results reducing “time-to-result” from 1 – 3 days to about one hour.

Broad detection
Test for up to 28 pathogens at once per test. Allows for syndromic testing to increase the chance of a positive result – while also allowing for the screening of common drug resistance genes.

Open-access
Run your own assays for customized testing or our validated assays.  The open-access feature of our genetic analyzer allows it to be rapidly configured to detect novel pathogens.

Connected
Electronically records data for interfacing with food safety records or medical records and for easy retrieval of historical data (trends)

For more information, please click here

Dr. Jack Regan | CEO, Founder

Dr. Regan invented the automated pathogen detection system that LexaGene is currently developing. He comes to LexaGene from Bio-Rad Laboratories, where he managed a team of scientists developing tests for detecting pathogens, cancer, and neurological disorders using droplet digital PCR. Prior to Bio-Rad, Jack helped QuantaLife, a startup company, bring its product from concept to commercialization. He has also worked on automated sample preparation at Applied Biosystems/Life Technologies and did his post-doctoral training at Lawrence Livermore National Laboratory, where he developed automated instruments to detect respiratory pathogens and bio-threat agents. His doctoral training at the University of California San Francisco focused on influenza viral replication.

Daryl Rebeck | President

Mr. Rebeck has over 15 years of capital market experience and an established international financial network. Mr. Rebeck was a Vice President and Senior Investment Advisor with Canada’s largest independent investment bank, Canaccord Genuity, where he was responsible for raising significant risk capital for growth companies, with a particular focus on natural resources and medical technology. Daryl has since worked to provide management expertise and grow shareholder value for organizations he has worked with. He served as Senior VP of Corporate Finance of TSX listed Auryn Resources, a $250 million market cap mining exploration company. Previous to this Mr. Rebeck was a consultant of corporate finance with Cayden Resources Inc., which was sold to Agnico Eagle Mining Limited for $205 million in November 2014.

Jeffrey Mitchell | CFO

Mr. Mitchell has over two decades of financial and SEC experience. Before joining LexaGene, he served in positions of increasing responsibility including Controller and Director of Finance, overseeing areas such as public company financial reporting, audits, and financial planning and analysis for Palomar Medical Technologies, Inc. which was publicly traded on the NASDAQ before Jeff helped orchestrate its sale to Cynosure in 2013 for $294 million. In addition to his many years at Palomar, Mr. Mitchell has served in numerous financial and strategic advisory roles for medical device, imaging, and diagnostic companies.

Greg Dale | VP of Product Development and Manufacturing

Mr. Dale has developed and manufactured more than a dozen products to date and is listed as an inventor on 28 issued U.S. patents on PCR and microfluidics devices. His medical device and in-vitro diagnostics product development experience includes work with instruments, microfluidics, sensors, disposables, reagents, wearables and implantables. Mr. Dale most recently served as Vice President, Product Development, Manufacturing and Quality at Emulate LLC; prior to Emulate, Mr. Dale served as General Manager and Senior Director of NGS (Next-Generation Sequencing) Engineering at Qiagen, where his team developed the Qiagen GeneReader NGS system using agile development methods. Mr. Dale has a degree in Mechanical Engineering from Virginia Tech.

Dr. Nathan Walsh | Director of Applications - Bioinformatics

Dr. Walsh has over 20 years experience interfacing between biology and bioinformatics. His experience with DNA sequence projects includes primer design, next-generation sequencing (NGS), cancer detection, microarrays, and pathway identification. Dr. Walsh most recently served as Head of Informatics at Bio-Rad's Digital Biology Center of Cambridge building a rapid-result next-generation sequencer; prior to that, he served as Senior Director of Informatics and IT to create drug hits from DNA encoded libraries. Dr. Walsh has been a post-doctoral fellow at Harvard Medical School with George Church and Brigham and Women's Hospital Department of Genetics. He has a Biochemistry degree from Brown University and a Ph.D. in Biology from MIT.

Dr. Manoj Nair | Senior Staff Scientist

Dr. Nair has over 7 years of experience developing and leading teams in the development of molecular diagnostic and pathogen typing assays in compliance with FDA IVD regulations for clinical diagnostics and AOAC guidelines for food safety applications. Before joining LexaGene, Dr. Nair served as Staff Scientist at Beckman Coulter Molecular Diagnostics and Senior Scientist at Roche Molecular Systems, where he helped the development of various qualitative and quantitative diagnostic assays for 510(k) clearance, PMA and CLIA waiver. Dr. Nair is also a trained veterinarian and specialized in the diagnosis and treatment of animal diseases in his early career. Dr. Nair conducted his postdoctoral studies at the University of Pennsylvania and Albany Medical College, concentrating on host-pathogen interactions in infections caused by bio-threat agents. His doctoral training at the University of Connecticut focused on the molecular pathogenesis of Cronobacter sakazakii and its detection in contaminated infant formula.

 

500 Cummings Center, Suite 4550
Beverly, MA 01915 USA

General inquiries: [email protected] | 800.215.1824

Investor Relations: [email protected]

For Corporate Information, please click here

View full LXG profile View Profile
View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.